Prostate Cancer

The FDA approved darolutamide tablets in combination with docetaxel for men with metastatic hormone-sensitive prostate cancer.

Enzalutamide monotherapy demonstrated significant treatment response among men on active surveillance for low- or intermediate-risk localized prostate cancer, according to phase 2 study results published in JAMA Oncology.

PSA screening appeared associated with lower prostate cancer-specific mortality among both black men and non-Hispanic white men, according to study results published in JAMA Oncology.

Phase 3 studies of pembrolizumab — with chemotherapy for metastatic castration-resistant prostate cancer and with lenvatinib for unresectable liver cancer — did not meet primary endpoints of survival, according to the agent’s manufacturer.

Donna Hansel, MD, PhD, has been named division head of pathology and laboratory medicine at The University of Texas MD Anderson Cancer Center.

Marc Botnick, MD, has been appointed regional medical director for radiation oncology at Cedars-Sinai Cancer.

Preoperative MRI led to significantly fewer postoperative complications among men undergoing prostatectomy for prostate cancer, according to study results.

Healio spoke with Daniel P. Petrylak, MD, about a presentation the American Urological Association meeting that focused on discontinuation rates of hormone therapy options among patients with advanced prostate cancer.

In this video, Daniel P. Petrylak, MD, discussed a presentation investigating androgen deprivation therapy plus upfront docetaxel in the treatment of patients 75 years or older with prostate cancer.

In this video, Matthew Zibelman, MD, associate professor at the department of hematology/oncology at Temple University Fox Chase Cancer Center, discusses some of the more consequential studies on prostate cancer at ASCO Annual Meeting.